Interventional therapy for AV valve disease-focus onmitral valve regurgitation. Position paper of the German Cardiac Society

Mitral and tricuspid valve regurgitation remain among the most prevalent valvular defects. The treatment strategy critically depends on the etiology of disease and differs with respect to the role of medical therapy, the timing of intervention, the strategy of whether to replace or repair, and the use of a transcatheter approach. Here, we summarize currently approved transcatheter therapies for the treatment of mitral and tricuspid regurgitation. Given the prevalence of disease and the high and increasing number of transcatheter procedures in particular for mitral valve regurgitation, the German Cardiac Society herewith publishes criteria for centers for transcatheter mitral valve therapy.